EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model

Michiyo Iba, Yeon-Joo Lee, Liam Horan-Portelance, Katherine Chang, Marcell Szabo, Robert A Rissman, Sungyong You, Eliezer Masliah, Changyoun Kim

Brain, Behavior, and Immunity · 2025

DOI: 10.1016/j.bbi.2024.09.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025. Verfasst von Michiyo Iba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Neuropathology Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Microglia, Mice, Transgenic, alpha-Synuclein, Disease Models, Animal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging, University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synucleinopathies are age-related neurological disorders characterized by the abnormal accumulation of α-synuclein (α-syn) in neuronal and non-neuronal cells. It has been proposed that microglial cells play an important role in synucleinopathy neuroinflammation, as well as homeostatically, such as in the clearance of α-syn aggregates in the brain. Here, we examined the effects of microglia on the pathogenesis of synucleinopathies by cell depletion in a mouse model of synucleinopathies. For this purpose, we treated non-transgenic (Non-tg) and α-synuclein transgenic (α-syn-tg) mice with pexidartinib (PLX3397), a tyrosine kinase inhibitor of colony-stimulating factor 1 receptor (CSF-1R). Neuropathological and immunoblot analysis confirmed that Iba-1 immunoreactive microglial cells were decreased by 95% following PLX3397 treatment in Non-tg and α-syn-tg mice. The level of total α-syn in the Triton X-insoluble fraction of brain homogenate was significantly decreased by microglial depletion in the α-syn-tg mice, while the level of Triton X-soluble human α-syn was not affected. Furthermore, the number of p-α-syn immunoreactive inclusions was reduced in α-syn-tg mice treated with PLX3397. Microglial depletion also ameliorated neuronal and synaptic degeneration in α-syn-tg mice, thereby resulted partially improving the motor behavioral deficit in α-syn-tg mice. Moreover, we demonstrated that microglia that survived post-PLX3397 treatment (PLX-resistant microglia) have lower expressions of CSF-1R, and microglial transcriptome analysis further elucidated that PLX-resistant microglia have unique morphology and transcriptomic signatures relative to vehicle-treated microglia of both genotypes; these include differences in definitive microglial functions such as their immune response, cell mobility, cell-cell communications, and regulation of neural homeostasis. Therefore, we suggest that microglia play a critical role in the pathogenesis of synucleinopathies, and that modulation of microglial status might be an effective therapeutic strategy for synucleinopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrogliaMice, Transgenicalpha-SynucleinDisease Models, AnimalAminopyridinesNeuronsPyrrolesBrainSynucleinopathiesAnimalsMiceReceptors, Granulocyte-Macrophage Colony-Stimulating FactorHumansMice, Inbred C57BL

Substanzen

pexidartinibalpha-SynucleinAminopyridinesPyrrolesCsf1r protein, mouseReceptors, Granulocyte-Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Molecular Neuropathology Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.
  • Departments of Urology and Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
  • Departments of Urology and Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic addres…
  • Molecular Neuropathology Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA; Division of Neuroscience, National Institute on Aging, National Institutes…
  • Molecular Neuropathology Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: changyoun.kim@nih.gov.

Förderung

  • NIA NIH HHS
  • National Institute on Aging
  • University of Pennsylvania
  • US Department of Defense
  • National Institute of Mental Health
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Iba, M., Lee, Y. J., Horan-Portelance, L., Chang, K., Szabo, M., Rissman, R. A., You, S., Masliah, E., & Kim, C. (2025). Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2024.09.016

Vancouver

Iba M, Lee YJ, Horan-Portelance L, Chang K, Szabo M, Rissman RA, et al. Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model. Brain, Behavior, and Immunity. 2025. doi:10.1016/j.bbi.2024.09.016

BibTeX
@article{Iba2025,
  author = {Iba, Michiyo and Lee, Yeon-Joo and Horan-Portelance, Liam and Chang, Katherine and Szabo, Marcell and Rissman, Robert A and You, Sungyong and Masliah, Eliezer and Kim, Changyoun},
  title = {Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  doi = {10.1016/j.bbi.2024.09.016}
}
Kostenlos starten →